Resumen
Use of molecules that reduce the levels of lipocalin-2 for the manufacture of a medicine for the treatment of abdominal aortic aneurysm (aaa). Use of an antibody capable of binding to lipocalin-2 for the manufacture of a medicament for the treatment of abdominal aortic aneurysm. Use of an antisense nucleic acid molecule capable of inhibiting the expression of the lipocalin-2 gene for the manufacture of a medicament for the treatment of abdominal aortic aneurysm. (Machine-translation by Google Translate, not legally binding)